

PPDC EPWG Meeting #4 Notes

Date: 2/25/2021

Charge Question #1 Continuation of Discussion

- Another question to consider- How to implement recommendations of the group?
- Additional feedback from last meeting (sections 1,2 and 3)-nothing additional

Hierarchy

- Not just viral hierarchy all organisms, easier to identify products, more thought out category lists
- Split list N into 3 different lists based upon type of virus
- Work upfront to help streamline product choices in times of crisis

Viral subgroup classification: List N

- Weaknesses-list was not as comprehensive due to not using all marketed names
- User perspective: confusing labels to laymen, and always should check registry number and not just the name
- Information is available but how its presented or given to the public should be improved
- Give information in the beginning of list N on how to use list N
- Registrant controlled branding info on list N, submitted in registration documents. Causing confusion for users.
- List supplemental products on list N and product names (reasons why not on list N-ask Tina/Kristen) on the registrants to inform the EPA
- Lag in the new labels after being put on list N
- FAQs were excellent

Product Eligibility criteria- efficacy claims

810s doesn't have clear info on LCL and nominal testing for EVP; give more specific protocols

Labeling

- How to quickly add on label claims (stickers or hang tags) acceptable to EPA?
- Outbreak Ready Logo
 - Or have a "outbreak ready" logo to have on products all the time
 - Expedited way to get logo in times of need for new products
 - Different logos for hierarchy of virus approved for
 - Focus groups to make sure it's understandable
 - Brainstorm how to get to process and challenges for logo idea (design, education, mechanism, etc.)
 - Informing the individual states and Canada- get their opinion on logo

- Using the most conservative contact time/dilution ratio so as not to confuse customer
- Label reading education for public and EVP education
- Alternative label language, a shorter text version instead of logo to have on label all the time

CSF and registered formulations

- Ran low on supplies due to the pandemic; had to petition EPA to add more suppliers.
Supply chain issues

Komal- open to charge question suggestions

Charge question 2: supply chain challenges and revisions during pandemic

- Should it be limited to only pandemics? (add “or other emergencies” or “event-based shortage”)
- Define emergency (make measurable)
- Only list N products could apply, but other products had supply chain issues too
- Flexibilities added, not temporarily. Why are they limited only to “dire times”?

Additional charge question: what happens after. Testing against actual organism. traditional means of making claims. what we learned through the pandemic process.